Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Fluidigm's peak revenue was $174.4M in 2024. The peak quarterly revenue was $46.7M in 2024(q4).
Fluidigm's revenue increased from $25.4m in 2009 to $174.4M currently. That's a 586.42% change in annual revenue.
| Fiscal year / year | Fluidigm revenue |
|---|---|
| 2009 | $25.4M |
| 2010 | $33.6M |
| 2011 | $42.9M |
| 2012 | $52.3M |
| 2013 | $71.2M |
| 2014 | $116.5M |
| 2015 | $114.7M |
| 2016 | $104.4M |
| 2017 | $101.9M |
| 2018 | $113.0M |
| 2019 | $117.2M |
| 2020 | $138.1M |
| 2021 | $130.6M |
| 2022 | $97.9M |
| 2023 | $106.3M |
| 2024 | $174.4M |
Rate Fluidigm's financial transparency
Fluidigm saw the greatest revenue growth in 2014, when revenue increased by 63.6%.
Fluidigm had the lowest revenue growth in 2022, when revenue changed by -24.99%.
| Year | Fluidigm growth |
|---|---|
| 2010 | 32%↑ |
| 2011 | 28%↑ |
| 2012 | 22%↑ |
| 2013 | 36%↑ |
| 2014 | 64%↑ |
| 2015 | -1%↓ |
| 2016 | -9%↓ |
| 2017 | -2%↓ |
| 2018 | 11%↑ |
| 2019 | 4%↑ |
| 2020 | 18%↑ |
| 2021 | -5%↓ |
| 2022 | -25%↓ |
| 2023 | 9%↑ |
| 2024 | 64%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2010 | - | - | - | $10.4M |
| 2011 | $8.7M | $10.6M | $10.6M | $13.0M |
| 2012 | $10.9M | $12.9M | $12.8M | $15.7M |
| 2013 | $14.5M | $17.5M | $18.3M | $20.9M |
| 2014 | $25.7M | $27.6M | $29.6M | $33.5M |
| 2015 | $26.7M | $28.6M | $28.6M | $30.7M |
| 2016 | $29.0M | $28.2M | $22.2M | $25.1M |
| 2017 | $25.5M | $23.9M | $24.7M | $27.7M |
| 2018 | $25.2M | $26.4M | $29.0M | $32.3M |
| 2019 | $30.1M | $28.2M | $26.5M | $32.4M |
| 2020 | $27.6M | $26.1M | $39.9M | $44.6M |
| 2021 | $32.8M | $31.0M | $28.5M | $38.3M |
| 2022 | $26.5M | $18.8M | $25.6M | $27.0M |
| 2023 | $25.1M | $27.7M | $25.4M | $28.2M |
| 2024 | $45.5M | $37.2M | $45.0M | $46.7M |
Do you work at Fluidigm?
Is Fluidigm transparent about its revenue structure?
| CEO | Stephen Linthwaite (Chris) |
| Industry | Software & Services |
| Company Type | Public |
| Employees Number | 535 |
| Date Founded | 1999 |
| Headquarters | South San Francisco, California |
| Number of Locations | 2 |
| Revenue | $174.4M |
| Net Income | -$190,098,000 |
| Gross Proft | $84.3M (2024) |
| PE Ratio | -2.43 |
| Tax Rate | -0.0% |
| Market Capitalization | $337.8M |
| Total Assets | $390,310,000 |
| Ticker | FLDM |
Fluidigm received early financing of $34.0M on 2001-11-12.
| Series | Round size | Date |
|---|---|---|
| Series C | $34M | 11/2001 |
| Series D | $21M | 01/2004 |
| Series D | $10M | 09/2005 |
| Series E | $37M | 01/2007 |
| Series Unknown | $10.7M | 09/2009 |
| Series Unknown | $7.5M | 11/2009 |
| Debt Financing | $5M | 01/2011 |
| Investors | Security type |
|---|---|
| GE Equity | Series C |
| Versant Ventures | Series C |
| Lehman Brothers Inc | Series C |
| InterWest Partners | Series C |
| Piper Jaffray Companies | Series C |
| EuclidSR Partners LP | Series C |
| Invus | Series D |
| EDBI Pte Ltd | Series D |
| Versant Ventures | Series D |
| InterWest Partners | Series D |
| Lehman Brothers Inc | Series D |
| Versant Ventures | Series D |
| InterWest Partners | Series D |
| EuclidSR Partners LP | Series D |
| ALLOY VENTURES | Series E |
| EDBI Pte Ltd | Series E |
| Versant Ventures | Series E |
| Lilly Ventures | Series E |
| InterWest Partners | Series E |
| Wasatch Advisors | Series E |
| Cross Creek | Series E |
| EuclidSR Partners LP | Series E |
| SMALLCAP WORLD FUND INC. | Series Unknown |
| ALLOY VENTURES | Series Unknown |
| EDBI Pte Ltd | Series Unknown |
| Versant Ventures | Series Unknown |
| InterWest Partners | Series Unknown |
| Lehman Brothers Inc | Series Unknown |
| Fidelity Contrafund | Series Unknown |
| EuclidSR Partners LP | Series Unknown |
Fluidigm's top competitor, Merck, earned an annual revenue of $64.2B.
Fluidigm's smallest competitor is Life Science with revenue of $230.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Beckman Coulter | $77,445 | $3.7B | 12,000 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,772 |
| Regeneron | $85,589 | $14.2B | 9,123 | 324 |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Bill & Melinda Gates Foundation | $114,538 | $4.8B | 1,602 | 19 |
| National Science Foundation | $56,854 | - | 1,700 | - |
| The New York Academy of Sciences | $66,984 | $24.4M | 785 | 4 |
| HHMI | $55,359 | $2.4B | 1,507 | 42 |
| Promega | $72,593 | $450.0M | 1,601 | 39 |
| National Inst for Pharmaceutical Tech & Ed | $53,149 | $700,000 | 3 | - |
Zippia gives an in-depth look into the details of Fluidigm, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Fluidigm. The employee data is based on information from people who have self-reported their past or current employments at Fluidigm. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Fluidigm. The data presented on this page does not represent the view of Fluidigm and its employees or that of Zippia.
Fluidigm may also be known as or be related to FLUIDIGM CORP, Fluidigm, Fluidigm Corp. and Fluidigm Corporation.